HOME >> MEDICINE >> NEWS
Cancer researcher Susan Horwitz wins Alpert prize for Taxol work

BOSTON-Susan Band Horwitz, Ph.D., the Falkenstein Professor of Cancer Research and Co-Chair of the Department of Molecular Pharmacology at the Albert Einstein College of Medicine, will today be awarded the 17th annual Warren Alpert Foundation Prize. The foundation recognizes Dr. Horwitz, a molecular pharmacologist, for her seminal contributions to the understanding of how the antitumor agent Taxol inhibits the growth of cancer cells. Her research helped pave the way for studies leading to approval of the plant compound for the treatment of ovarian, breast and lung cancers. The foundation will award Dr. Horwitz a $150,000 prize.

"One thing that Mr. Alpert stipulated when he developed this prize was that it should go to someone who had already made major contributions to helping patients. The impact of Susan's work has been quite extraordinary in the cancer field," said Professor Dominick Purpura, MD, Dean of Albert Einstein College of Medicine, who nominated Dr. Horwitz for the prize. In fact, earlier this year, shortly after Dr. Horwitz was selected as winner of the prize, she was acknowledged by her peers for her contributions to cancer research when she was elected to the National Academy of Sciences.

In the US, Taxol was first approved by the Food and Drug Administration (FDA) for the treatment of refractory ovarian cancer in 1992. Approval for metastatic breast cancer followed in 1994, and more recently for non-small cell lung cancer in 1999. "Taxol has become one of the most valuable cytotoxic chemotherapeutic agents we have in clinical oncology. It has proven effective in ovarian, breast, lung, and head and neck cancer and it has contributed immensely to the quality of life of cancer patients," said Larry Shulman, associate professor of medicine at the Dana-Farber Cancer Institute, Boston. The drug has been used in well over a million patients worldwide.

In 1977, Dr. Horwitz was approached by the National Cancer Institute to study the
'"/>

Contact: john_lacey@hms.harvard.edu
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
22-Jun-2005


Page: 1 2 3

Related medicine news :

1. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
2. Cancer research summaries
3. Cancer on the agenda of the Portuguese EU Council Presidency
4. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
5. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
6. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
7. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
8. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
9. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
10. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research
11. Cancer-fighting foods, supplements explored in day-long symposium, March 25

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cancer researcher Susan Horwitz wins Alpert prize for Taxol work

(Date:11/21/2014)... VogueQueen has released 18 new beach wedding ... coming holiday season. People who register at VogueQueen.com now ... The beach wedding dresses from VogueQueen.com have been very ... the premium quality fabrics and dedicated craftsmanship. These products ... environment, they would bring more fun to a lady’s ...
(Date:11/21/2014)... 2014 Midway through the research period ... (AIS) annual Directory of Health Plans, preliminary data shows ... of Health Plans is a comprehensive resource with enrollment ... the U.S. The 2015 edition will be ... Directory and Databases Division, the company’s exclusive in-house research ...
(Date:11/21/2014)... 2014 TruDenta, the creator of a ... and other jaw-related symptoms, has reported a nationwide rise ... head pain, neck pain, TMJ (temporomandibular joint) disorder, jaw ... have seen a 52% increase in the number of ... 300 doctors and their teams in 47 states are ...
(Date:11/21/2014)... 2014 Recently, DressVe.com , a renowned ... announced a new collection of fashion accessories. Furthermore, the company ... up to 95% off, on all its fashion items. Also, ... to the CEO of the company, their wedding dresses and ... now available at greatly discounted rates. , The CEO ...
(Date:11/21/2014)... November 21, 2014 Recently, TideStore.com, a ... accessories, has announced its special offer TideStore Thanksgiving ... items at TideStore.com are now provided with big discounts. ... 25. People can enjoy an extra 10% discount with ... their email addresses and have opportunities to win free ...
Breaking Medicine News(10 mins):Health News:Beach Wedding Dresses on Sale for the Coming Holiday Season at VogueQueen.com 2Health News:Data from Atlantic Information Services’s Forthcoming Directory Shows Volatility in U.S. Health Care Market 2Health News:National Rise In Patients Seeking Headache Relief 2Health News:DressVe.com Announces Its 2014 Special Friday Sales 2Health News:Thanksgiving Sales from TideStore.com 2
(Date:11/21/2014)... November 2014 Clementia ... gegeben, dass die Europäische Arzneimittel-Agentur (European ... als Orphan-Medizinprodukt an Palovarotene vergeben hat, ... Behandlung von Fibrodysplasia ossificans progressiva (FOP). ... genetische Krankheit, die von schmerzhaften, wiederkehrenden ...
(Date:11/21/2014)... DUBLIN, Ohio and MELVILLE, N.Y. ... (NYSE: CAH ), one of the world,s ... (NASDAQ: HSIC ), the world,s largest provider ... animal health and medical practitioners, today announced that the ... provide one of the most comprehensive service and product ...
(Date:11/21/2014)... YORK , Nov. 20, 2014  Market research firm ... the "Year of The Buy, in the medical device ... for medical devices will produce just 3% growth this ... actions, including acquisitions of product lines and entrance by ... annual survey of medical devices, The Global Market ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
Cached News: